SecBot SecBot

ZLAB drug pipeline

Zai Lab Ltd · 5 rated drugs
$23.47
−4.6% 1-day · Nov 16
Next catalyst
Nov 30, 2026
povetacicept PDUFA date · in 14 days
Typical move on FDA news
±4.4%
1-day, median of 8 events
IV rank
No data
No current options data
Rated drugs
5
5 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Nov 30, 202614d
    povetacicept
    PDUFA date · immunoglobulin A nephropathy (IgAN)

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in both the US (since September 2024) and China (since June 2026).

KarXT xanomeline/trospium chloride Updated Nov 7

What to watch

KarXT is already approved and launching in China, so the next stock-moving events for Zai Lab around this drug are commercial milestones: NRDL (national reimbursement) negotiation outcomes, quarterly sales growth trends, and any label expansion for Alzheimer's psychosis or bipolar mania that Zai Lab might pursue in China. The next major binary catalyst for Zai Lab overall is the November 30, 2026 PDUFA date for povetacicept in IgAN, not KarXT.

Bull case
  • First-in-class mechanism: KarXT is the first schizophrenia drug with a novel mechanism in over 50 years, addressing a massive unmet need across 8 million+ patients in China alone.
  • Approved and launching: NMPA approval secured in December 2025 and commercial launch in China began June 2026, with early launch trends described as encouraging by management.
  • Strong institutional accumulation: Multiple tracked managers (FMR LLC, Goldman Sachs, Woodline Partners) doubled or initiated positions in Zai Lab during Q2 2026, signaling confidence in the commercial opportunity.
Bear case
  • No near-term binary catalyst: With both US and China approvals secured, there is no upcoming PDUFA or pivotal readout for KarXT to drive a sharp re-rating for Zai Lab.
  • Commercial execution risk: KarXT is a new entrant in China's schizophrenia market; NRDL reimbursement inclusion is not guaranteed and pricing negotiations could pressure margins.
  • Insider selling: CFO Chen Yajing and director Lis William sold shares in August 2026 (some under 10b5-1 plans), which may signal limited near-term upside conviction from insiders.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized. NUZYRA has been marketed in China since December 2021 and in the US since October 2018.

NUZYRA omadacycline Updated Nov 7

What to watch

NUZYRA itself has no upcoming binary catalyst; it is an approved, marketed product contributing steady growth. The next major catalyst for Zai Lab is the November 30, 2026 PDUFA for povetacicept in IgAN, a separate drug. Watch Q4 2026 earnings for NUZYRA's continued NRDL-driven sales trajectory and any label-expansion developments in China.

Bull case
  • NUZYRA is already approved and commercialized in China (NMPA Category 1 innovative drug, December 2021) with both oral and IV formulations for CABP and ABSSSI, removing regulatory risk.
  • NUZYRA was renewed in China's 2025 National Reimbursement Drug List (NRDL), ensuring continued patient access and volume growth through government reimbursement.
  • In Q3 2026, NUZYRA was cited as a key driver of Zai Lab's sequential product revenue growth, supported by increased market coverage and penetration.
Bear case
  • NUZYRA is one of eight commercial products in Zai Lab's portfolio and is not the dominant revenue driver; its contribution is modest relative to the overall business.
  • As a tetracycline-class antibiotic, NUZYRA faces generic competition risk in China as patent protection erodes, and competition from established antibiotics could limit market share.
  • Antimicrobial stewardship policies in China aimed at curbing antibiotic overuse may restrict broad application of NUZYRA, capping growth potential.
● neutral
Impact
PhaseApproved (marketed device)
Time to marketAlready marketed in China for GBM. The pancreatic cancer indication is under NMPA review (Innovative Medical Device Designation granted August 2025; submission planned H2 2025), with no confirmed approval date yet.

OPTUNE tumor treating fields therapy Updated Nov 7

What to watch

Watch for NMPA acceptance and a potential approval decision for OPTUNE in pancreatic cancer, which would open a large new addressable market in China. However, the lack of a confirmed submission or decision date as of Q3 2026 earnings means this catalyst is not imminent. Monitor quarterly revenue trends for Optune in GBM, as competition is eroding market share. Zai Lab's next major near-term catalyst is the November 30, 2026 PDUFA date for povetacicept in IgA nephropathy, a separate pipeline asset.

Bull case
  • OPTUNE is a novel, non-invasive physical cancer therapy with a differentiated mechanism that avoids systemic toxicity, already approved in China for GBM and in the US for GBM and pancreatic cancer.
  • The pancreatic cancer opportunity in China is large: approximately 134,000 new cases annually with a five-year survival rate under 10%, and the Phase 3 PANOVA-3 trial showed a statistically significant overall survival improvement (16.2 vs 14.2 months).
  • Zai Lab has an exclusive license for Greater China from Novocure, and the NMPA granted Innovative Medical Device Designation for the pancreatic cancer indication, which can expedite regulatory review.
Bear case
  • OPTUNE revenue is declining in China due to evolving competition in the glioblastoma market, as noted in Zai Lab's Q3 2026 earnings (November 5, 2026).
  • The device-based therapy requires patients to wear the device most of the day, which may limit adoption versus oral or infusion-based cancer treatments.
  • The pancreatic cancer NMPA submission timeline is uncertain (planned H2 2025 but no confirmed filing or approval date as of November 2026), and the addressable market for a wearable device in pancreatic cancer is unproven in China.
● neutral
Impact
PhasePhase 3
Time to marketAt least 2-4 years. The Phase 3 DLLEVATE trial is just being initiated, and a registrational path for NEC is also in planning. If Phase 3 data is positive, a BLA submission would follow, putting potential approval in the 2028-2030 timeframe.

zocilurtatug pelitecan Updated Oct 23

What to watch

Watch for the initiation and enrollment updates of the Phase 3 DLLEVATE trial and any NEC registrational data timeline. The PIPE's strong institutional participation (TCGX-led, with RA Capital, Wellington, Frazier) signals conviction, but the ~9% dilution is a near-term overhang. The stock's next major binary will be the DLLEVATE topline readout, no date set yet, but the $250M raise suggests a global pivotal program is imminent.

Bull case
  • 81.8% confirmed ORR in 1L ES-SCLC at ESMO 2026 is a standout efficacy signal that compares very favorably to standard-of-care and competing DLL3 assets (Legend's CAR-T showed 28.6% ORR at ASCO 2026)
  • Only 9.1% Grade 3 TRAEs, a clean safety profile for an ADC, suggesting a wide therapeutic window
  • $250M PIPE led by TCGX with participation from RA Capital, Wellington, Frazier, Cormorant, Balyasny, sophisticated healthcare investors who did deep diligence, validating the asset's promise
Bear case
  • ~9% dilution from the $250M PIPE (11.34M ADSs at $22.04) is a near-term overhang on the stock
  • DLL3 space is getting crowded: Legend Biotech (LB2102 CAR-T), Molecular Partners (MP0712 Radio-DARPin), and Roche/Zymeworks (ZW209 trispecific engager licensed to Roche, all targeting the same patient population
  • Phase 3 data is not yet available, the 81.8% ORR is from a smaller Phase 1/2 study and may not replicate in a larger randomized trial
● neutral
Impact
PhasePhase 1/1b
Time to marketYears away. ZL-1503 is in Phase 1/1b first-in-human testing. Even if development proceeds smoothly, regulatory filing would be at least 3-5 years out for a Phase 3 program in atopic dermatitis.

ZL-1503 Updated Nov 7

What to watch

The next catalyst is a Phase 1/1b healthy-volunteer data poster at ACAAI on November 13, 2026 (Friday of next week). Watch for safety, PK, and biomarker signals. Clean data could modestly support the thesis; any safety signal or unremarkable PK would have little negative impact given the early stage. The much larger near-term binary for Zai Lab is the povetacicept PDUFA for IgAN on November 30, 2026.

Bull case
  • ZL-1503 is a potential first-in-class bispecific antibody that simultaneously blocks both the IL-13 (inflammatory) and IL-31 (itch) pathways, aiming to disrupt the entire itch-scratch-inflammation cycle in a way no single-target biologic does.
  • Preclinical data showed sustained suppression of both inflammation and pruritus over 112 days in animal models, with a favorable safety profile and extended half-life, suggesting potential for less frequent dosing.
  • The atopic dermatitis market is large (over $3 billion globally) and growing, with room for differentiated therapies that address both itch and inflammation in a single agent.
Bear case
  • At least four biologics are already approved for moderate-to-severe atopic dermatitis (dupilumab, tralokinumab, lebrikizumab, nemolizumab), making this a crowded competitive field where a Phase 1 bispecific would need to show clear differentiation to justify years of further development.
  • The upcoming ACAAI data comes from healthy volunteers only, not atopic dermatitis patients, so it covers safety, PK, and biomarkers rather than efficacy, limiting its ability to move the commercial thesis.
  • ZL-1503 is one of many pipeline assets at a commercial-stage company with $441M in trailing revenue; it represents a small fraction of Zai Lab's overall value, so even a strong readout is unlikely to drive significant share-price movement.

Other drugs in filings and trials

no drug report yet
  • povetacicept Next: PDUFA date · Nov 30, 2026 Last: BLA filed · Jun 30, 2026
  • VYVGART Last: PDUFA decision · May 10, 2026

Past FDA events & how the stock moved

8 events
DateDrugEvent1 day5 days
Jun 30, 2026PovetaciceptBLA filed+4.0%+7.3%
Jun 1, 2026povetaciceptBLA filed−3.0%−6.8%
May 10, 2026VYVGARTPDUFA decision+5.3%+10.7%
May 10, 2026VYVGARTPriority review+5.3%+10.7%
Jan 1, 2026VYVGARTPriority review−1.8%+4.9%
Dec 1, 2025povetaciceptFast Track−4.4%−6.7%
Dec 1, 2025povetaciceptOrphan drug designation−4.4%−6.7%
Dec 1, 2025KarXTApproval−4.4%−6.7%